CervoMed Analyst Price Targets - Benzinga

CervoMed Inc

CRVONASDAQ

Trade with Public

Trade with Public

$2.25

-0.04-1.75%

마지막 업데이트: Oct 15, 5:12 PM

$2.28

-0.01-0.44%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 주식 보고서

CervoMed Analyst Price Targets - Benzinga

CervoMed Analyst Price Targets

Wall Street analyst price targets and consensus rating for CervoMed (CRVO).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$27Upside to Avg. PT+1064.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Aug 12, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Aug 10, 2026	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$27→$18
Jul 15, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Jul 13, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Jul 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Apr 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Apr 22, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Apr 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Mar 19, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Mar 18, 2026	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$19→$11
Mar 18, 2026	Chardan Capital	Daniil Gataulin	PT Raise	Buy	$15→$21
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Mar 5, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$15
Mar 4, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Feb 18, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Dec 18, 2025	Cantor Fitzgerald	Pete Stavropoulos	Initiate	Overweight	—
Dec 18, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Dec 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Dec 2, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk